relugolix is under development by myovant sciences and takeda for the treatment of uterine fibroids in countries besides japan such as the united states. myovant sciences intends to submit a new drug application of relugolix for uterine fibroids in the united states in the fourth quarter of 2019. relugolix is also under development for the treatment of endometriosis and prostate cancer in the united states, japan, and other countries. as of february 2019, it is in phase iii clinical trials for these indications.